Literature DB >> 6571788

Idiopathic refractory sideroachrestic anemia (IRSA) progressing to acute mixed lymphoblastic-myelomonoblastic leukemia. Case report and review of the literature.

R Hehlmann, B Zönnchen, E Thiel, B Walther.   

Abstract

A longitudinal observation of a patient with idiopathic refractory sideroachrestic anemia (IRSA) progressing to acute mixed lymphoblastic-myelomonoblastic leukemia is reported. The leukemia was characterized by morphology, immunological cell markers, and dissociated clinical responsiveness to vincristine/prednisone and arabinosylcytosine/6-thioguanine. Attention is paid to the hematological changes prior to leukemia development. Acute leukemia was best heralded in this patient by a severe deterioration of dyserythropoiesis and by an increase of blasts in the marrow to more than 5%. The observed preleukemic features are compared to those described in the literature.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6571788     DOI: 10.1007/bf00320001

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  32 in total

1.  SIDEROBLASTIC ANAEMIA IN MAN: OBSERVATIONS ON SEVENTY CASES.

Authors:  B H MACGIBBON; D L MOLLIN
Journal:  Br J Haematol       Date:  1965-01       Impact factor: 6.998

2.  Chronic refractory anemia with sideroblastic bone marrow; a study of four cases.

Authors:  S E BJORKMAN
Journal:  Blood       Date:  1956-03       Impact factor: 22.113

3.  Refractory sideroblastic and nonsideroblastic anemia: a review of 27 cases.

Authors:  W Geschke; E Beutler
Journal:  West J Med       Date:  1977-08

4.  Effect of pyridoxine plus chronic phlebotomy on the function and morphology of bone marrow and liver in pyridoxine-responsive sideroblastic anemia.

Authors:  J D Hines
Journal:  Semin Hematol       Date:  1976-04       Impact factor: 3.851

5.  The preleukemic syndrome.

Authors:  J W Linman; M I Saarni
Journal:  Semin Hematol       Date:  1974-01       Impact factor: 3.851

6.  Abnormal iron incorporatin, survival protoporphyrin content and fluorescence of one red cell population in preleukemic sideroblastic anemia.

Authors:  G F Riedler; P W Straub
Journal:  Blood       Date:  1972-09       Impact factor: 22.113

7.  Preleukemia. The hematologic syndrome preceding acute leukemia.

Authors:  M I Saarni; J W Linman
Journal:  Am J Med       Date:  1973-07       Impact factor: 4.965

8.  Preleukemic states.

Authors:  R V Pierre
Journal:  Semin Hematol       Date:  1974-01       Impact factor: 3.851

9.  Multimarker classification of acute lymphoblastic leukemia: evidence for further T subgroups and evaluation of their clinical significance.

Authors:  E Thiel; H Rodt; D Huhn; B Netzel; H Grosse-Wilde; K Ganeshaguru; S Thierfelder
Journal:  Blood       Date:  1980-11       Impact factor: 22.113

10.  Human preleukemia.

Authors:  H P Koeffler; D W Golde
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

View more
  5 in total

Review 1.  Transformation of myelodysplastic syndrome to acute lymphoblastic leukemia: a case report and review of the literature.

Authors:  Norihide Sato; Tomonori Nakazato; Masahiro Kizaki; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

Review 2.  Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia.

Authors:  D M Layton; G J Mufti
Journal:  Blut       Date:  1986-12

3.  The nature of blast cells in myelodysplastic syndromes evolving to acute leukaemia.

Authors:  J F San Miguel; M González; M C Cañizo; J P Anta; J Hernández; F Ortega; L Borrasca
Journal:  Blut       Date:  1986-06

4.  Sideroachrestic anemia with iron loading: treatment with desferrioxamine.

Authors:  W G Zoller; R Hehlmann
Journal:  Klin Wochenschr       Date:  1986-05-02

5.  Myelodysplastic syndrome with myelofibrosis transformed to a precursor B-cell acute lymphoblastic leukemia: a case report with review of the literature.

Authors:  Ayed A Algarni; Mojtaba Akhtari; Kai Fu
Journal:  Case Rep Hematol       Date:  2012-03-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.